Use of immune checkpoint inhibitors (ICIs) after prior ICI in metastatic renal cell carcinoma (mRCC): Results from a multicenter collaboration.
Praful Ravi(Dana-Farber Cancer Institute), Toni K. Choueiri(Harvard University), Ziad Bakouny(Dana-Farber Cancer Institute), Charlene Mantia(Dana-Farber Cancer Institute), K Sorenson(Mayo Clinic), Ajjai Alva(Michigan Medicine), Rana R. McKay(University of California San Diego), Christopher Su(Fred Hutch Cancer Center), Bradley A. McGregor(Harvard University), Vivek Narayan(Hospital of the University of Pennsylvania), Brian A. Costello(Mayo Clinic in Arizona), Xīn Gào(Qingdao University), David F. McDermott(Beth Israel Deaconess Medical Center), Neeraj Agarwal(University of Utah), Nityam Rathi(Cleveland Clinic)
Cited by 1
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k